Barnet Dulaney Perkins Eye Center | Phoenix

Research site

(Unclaimed)

Location

4800 N 22nd Street, Phoenix, Arizona, United States of America

Site insights

Top conditions

Top treatments

Riboflavin

RBX2660

OC-01

Faricimab

Ranibizumab

TNX-102

Abicipar Pegol

RO7446603

Aflibercept

Relugolix

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 19 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Biological: 4D-150 IVT (3E10 vg/eye)

Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

A Phase 3B Study to Evaluate Bone Mineral Density with Long-Term Use of Relugolix Combination Tablet in Women with Uterine Fibroids or Endometriosis

The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for...

Enrolling

Uterine Fibroids

Endometriosis

Drug: Relugolix Combination Tablet

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (THAMES)

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME)....

Enrolling

Diabetic Macular Edema

Drug: Faricimab

Drug: Aflibercept

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema (ELEVATUM)

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Active, not recruiting

Diabetic Macular Edema

Drug: Faricimab

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling

Neovascular Age-Related Macular Degeneration

Drug: PDS Implant with Ranibizumab 100 mg/mL

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE®)

ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without...

Enrolling

Diabetic Retinopathy (DR)

Center-Involved Diabetic Macular Edema (CI-DME)

Genetic: ABBV-RGX-314 Dose 4

Biological: Aflibercept